What is the maximum daily dose of guanfacine (immediate‑release and extended‑release) for adults, children, and adolescents, and how should dosing be adjusted when using strong CYP3A4 inhibitors or inducers?

Maximum Dose of Guanfacine

The maximum daily dose of guanfacine extended-release is 7 mg/day (or 0.12 mg/kg/day) for children and adolescents aged 6-17 years, while immediate-release guanfacine for hypertension should not exceed 3 mg/day, with doses above this level significantly increasing adverse reactions. 1, 2

Dosing by Formulation and Population

Extended-Release Guanfacine (Intuniv XR)

• Starting dose: 1 mg once daily 1
• Titration: Increase by 1 mg per week based on response and tolerability 1
• Target dose range: 0.05 to 0.12 mg/kg/day or 1 to 7 mg/day 1
• Maximum dose: 7 mg/day 1
• Approved population: Children and adolescents aged 6-17 years (Canada); ages 6 and older (US) 1

Immediate-Release Guanfacine

• Starting dose: 1 mg daily at bedtime 2
• Titration: May increase to 2 mg after 3-4 weeks if needed 2
• Maximum dose: 3 mg/day (doses above this significantly increase adverse reactions) 2
• Primary indication: Hypertension in adults 2

Critical Dose Adjustments with CYP3A4 Interactions

Guanfacine is primarily metabolized via CYP3A4, requiring substantial dose modifications when co-administered with CYP3A4 inhibitors or inducers. 3, 4

With Strong or Moderate CYP3A4 Inhibitors

• Reduce guanfacine dose to 50% of the usual target dose 4, 5
• Examples include:
  • Erythromycin 500 mg three times daily (increases guanfacine AUC by 2.31-fold) 4
  • Fluconazole 200 mg daily (increases guanfacine AUC by 1.98-fold) 4
  • Ketoconazole and other strong inhibitors 4

With Strong or Moderate CYP3A4 Inducers

• Consider titrating guanfacine up to double the usual target dose over 1-2 weeks 4, 5
• Examples include:
  • Efavirenz 400 mg daily (reduces guanfacine AUC to 58% of baseline) 4
  • Efavirenz 600 mg daily (reduces guanfacine AUC to 33% of baseline) 4
  • Carbamazepine (clinically relevant inducer based on case reports) 5

Important caveat: The package insert correction factors may underestimate the magnitude of interaction, particularly with potent inducers like phenobarbital, based on case report evidence and experience with other CYP3A4-metabolized medications. 5

Weight-Based Dosing Considerations

• Rule of thumb: Approximately 0.1 mg/kg once daily for weight-adjusted dosing 3
• Optimal therapeutic range: Weight-adjusted doses >0.08 mg/kg but ≤0.12 mg/kg may provide additional clinical benefits if tolerated 6
• For adolescents weighing >70 kg, such dosing may require doses exceeding 4 mg/day, which is supported by pharmacokinetic data showing appropriate clearance at higher weight-adjusted doses 6

Safety Profile at Maximum Doses

Most common adverse effects are dose-dependent and include somnolence (36-39%), headache (28.5%), fatigue (20.1%), dry mouth (28-54%), and constipation (15%). 3, 2, 7

Cardiovascular Effects

• Dose-dependent decreases in blood pressure and heart rate 3, 8, 6
• Small mean changes at final assessment: pulse -5.5 bpm, systolic BP +0.6 mmHg, diastolic BP +0.2 mmHg 7
• Blunted physiologic BP response upon standing in dose-related manner 6
• Risk of bradycardia, hypotension, and syncope 3, 8

Discontinuation Considerations

• Must taper rather than abruptly discontinue to avoid rebound hypertension 8, 2
• Rebound occurs 2-4 days after discontinuation (delayed compared to clonidine due to longer half-life) 2
• In most cases, blood pressure returns to pretreatment levels slowly without ill effects 2

Comparative Context

Guanfacine is approximately ten times less potent than clonidine but has higher specificity for alpha-2A receptors, resulting in fewer sedative effects. 3 The maximum dose of clonidine for ADHD is 0.4 mg/day, significantly lower than guanfacine's 7 mg/day maximum. 1, 3